FOR IMMEDIATE RELEASE
Orthomolecular Medicine News Service, October 13, 2020
Commentary by Patrick Holford

(OMNS Oct 13, 2020) The world’s first randomized placebo controlled trial designed to test high dose intravenous vitamin C for treatment of COVID-19 has reduced mortality in the most critically ill patients by two thirds. [1] The study, headed by Professor Zhiyong Peng at Wuhan’s Zhongnan University Hospital, started in February and gave every other critically ill COVID-19 patient on ventilators either 12,000 milligrams (mg) of vitamin C twice daily or sterile water in their drip. Neither the patient nor the doctors knew who was getting vitamin C or placebo so the trial was "double blind." This is the ‘gold standard’ of research design.
Overall, 5 out 26 people (19%) died in the vitamin C group while 10 out of 28 (36%) receiving the placebo died. That means that vitamin C almost halved the number of deaths. Those on vitamin C were 60% more likely to survive.

Keep reading: https://orthomolecular.activehosted....0dd76442e.180&